Update on Chemotherapy in the Treatment of Urothelial Carcinoma

Table 1

Second-line single agent chemotherapy trials in advanced urothelial carcinoma.

Reference	Agent	Subjects	Response rate (%)	Survival (months)
Witte et al. [4]	Ifosfamide	56	20	5.5
McCaffrey et al. [5]	Docetaxel	30	13	9
Lorusso et al. [6]	Gemcitabine	35	23	5
Albers et al. [7]	Gemcitabine	30	11	8.7
Vaughn et al. [8]	Paclitaxel	31	10	7.2
Joly et al. [9]	Paclitaxel	45	9	7
Sweeney et al. [10]	Pemetrexed	47	28	9.6
Galsky et al. [11]	Pemetrexed	13	8	Not reported
Dreicer et al. [12]	Ixabepilone	45	12	8
Sridhar et al. [13]	Nab-paclitaxel	48	33	Not reported
Bellmunt et al. [14]	Vinflunine	307	9	6.9